Valeant Said to Replace Up to Five Board Members This Week

  • Chairman Ingram, head of audit committee may step down
  • Drugmaker shaking up strategy, governance as it awaits new CEO

Valeant Senate Hearing in Three Minutes

Valeant Pharmaceuticals International Inc. may replace as many as five directors as soon as Friday, according to a person familiar with the matter, as the company overhauls its strategy and governance and awaits its new chief executive officer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.